NSC-348884 is primarily used in biochemical and pharmacological research as an inhibitor of the NPM-ALK fusion protein, which is associated with certain types of lymphoma, particularly anaplastic large cell lymphoma (ALCL). It has demonstrated the ability to suppress the activity of ALK-dependent signaling pathways, leading to reduced proliferation and induction of apoptosis in cancer cell lines expressing the fusion protein. Due to its specific mechanism of action, it serves as a valuable tool compound in studies aimed at understanding oncogenic signaling and evaluating potential therapeutic strategies targeting ALK-mediated cancers. Its use remains confined to preclinical research and is not approved for clinical use.